PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
PROVECTUS BIOPHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026
- Market cap
- $20.55M
- P/E (TTM)
- –
- Dividend yield
- –
Provectus Biopharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $20.55M | $164.85M |
| Enterprise Value | $19.38M | $87.06M |
Income (trailing twelve months)
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$4.58M | -$21.44M |
| Net Income | -$4.75M | -$22.46M |
| EBITDA | -$4.58M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Returns
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -432.6% | -41.0% |
Growth
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -30.2% | 2.25% |
Balance sheet
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.16M | $62.42M |
| Net Cash (Debt) | $1.16M | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$6.28M | $48.79M |
| Book Value Per Share | -$0.01 | $1.36 |
| Tangible Book Value | -$6.28M | $23.06M |
| Working Capital | -$6.34M | $75.77M |
Financial position
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.18 | 3.30 |
| Quick Ratio | 0.15 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.43M | -$12.35M |
Efficiency
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$791.56K | -$703.34K |
| Employee Count | 6 | 74 |
Dividends and yields
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -23.1% | -22.7% |
Shares
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 420,280,000 | 58,179,650 |
| Shares Change (YoY) | 0.02% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 334,410,000 | 49,173,100 |
| Shares Held by Insiders | 20.4% | 11.6% |
| Shares Held by Institutions | 0.03% | 59.4% |
Scores
| Measure | Provectus Biopharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -265.74 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Provectus Biopharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.